Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Javelin Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. We’ll take our first question from Gary Nachman - Leerink Swann. Gary Nachman - Leerink Swann First question on the Ereska data; Marty, what did you mean that the outcome could change in the future after you examine all aspects of the data,...
- Earnings calls 2009-08-11
- Safeguard Scientifics, Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions Our first question comes from Robert Labick with CJS Securities. Robert Labick - CJS Securities Couple of questions, first I wanted to ask you. You talked a little bit about on the sell registration on Clarient. Could you maybe give us a...
- Earnings calls 2009-08-05
- Antigenics, Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. Your first question comes from the line of Ren Benjamin - Rodman & Renshaw. Ren Benjamin - Rodman & Renshaw Starting off with Oncophage, thanks for the review of the clinical data. I thought that the subset analysis actually got split into...
- Earnings calls 2009-07-30
- Ligand Pharmaceuticals Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Our first question comes from Joe Pantginis from Merriman Curhan Ford. Your line is now open. Joe Pantginis – Merriman Curhan Ford Hi guys, how are you? Thanks for taking the call. Couple quick questions if you don’t mind, I guess maybe in the order...
- Earnings calls 2009-05-06
- WPT Enterprises, Inc. F1Q09 Earnings Call Transcript
- Question-and-Answer Session Operator Operator instructions Your first question comes from the line of Clint Morrison - Feltl & Company. Clint Morrison - Feltl & Company Just one quickly on ClubWPT, I think you have said 15,000 subscribers of which 1,000 were trials. We have got 14,000 game subscribers. Is...
- Earnings calls 2009-05-04
- Cytokinetics, Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Your first question comes from Mark Monane of Needham & Company. Glenn Hanus - Needham & Company Hi. This is Glenn answering for Mark. My first question is on the recently initiated Phase IIa trial for multiple dosing for intermediate and oral for the PK....
- Earnings calls 2009-04-30
- Phorm trials in Korea in first non-UK venture
- London-based startup Phorm is trialling its behavioural targeting technology with South Korean broadband provider KT. The company claims its technology can link online advertising, media and content to users’ interests without compromising privacy. The deal is Phorm’s first outside the...
- Articles 2009-03-30
- Molecular Insight Pharmaceuticals, Inc.Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you, Mr. Babich. Operator Instructions Your first question comes from the line of Marko Kozul from Jefferies. Please proceed. Marko Kozul - Jefferies & Company Hi, congratulations on your recent progress. John Babich Thank you, Marko. Marko Kozul - Jefferies & Company John, first...
- Earnings calls 2009-03-16
- Javelin Pharmaceuticals, Inc., Q4 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. We will take our first question from Gary Nachman with Leerink Swann. Gary Nachman - Leerink Swann Hi, good morning. Marty, first what exactly are you looking for the Dyloject observational study? How long are patients actually being tracked, and do you...
- Earnings calls 2009-03-12
- ArQule, Inc. Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Mark Monane from Needham & Company. Please proceed. Mark Monane – Needham & Company Thank you, good morning, and thank you for the comprehensive review. Brian Schwartz Good morning. Mark Monane – Needham & Company Glenn...
- Earnings calls 2009-03-05
- Savient Pharmaceuticals, Inc, Q4 Year Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions And we'll go first to Eric Varma with Leerwink Swann. Eric Varma – Leerwink Swann Hey, good morning I had a quick question on a follow-on about febuxostat. If you can just kind of remind us how the CV incidents compare between...
- Earnings calls 2009-02-26
- Isis Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. And we will take our first question from Joseph Schwartz from Leerink Swann. Joseph Schwartz – Leerink Swann Llc Great. Good morning. Thanks for taking the question. I was wondering if you can give us an update on severe high cholesterol study, how...
- Earnings calls 2009-02-25
- Targacept, Inc. Q4 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. And our first question comes from the line of Terence Flynn with Lazard Capital Markets. Please proceed sir. Terence Flynn – Lazard Capital Markets Hi, good afternoon. Thanks for taking the questions. Just wondering around some of the start of these Phase...
- Earnings calls 2009-02-12
- Osiris Leaps on $1.38 Billion Genzyme Stem-Cell Deal
- Eben Tessari submits: Genzyme GENZ announced that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult mesenchymal stem cell treatments that hold significant potential to treat a wide range of diseases. These stem-cell products are designed to provide therapeutic...
- External links 2008-11-05
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Tom Petters Goes To Trial In History's Second-Largest Hedge Fund Ponzi Scheme
- Ed's Note: An earlier version of this article incorrectly stated that Fingerhut had filed for bankruptcy protection. That correction has been made. In Minnesota this week, a trial is quietly getting underway to prosecute the alleged mastermind behind the second largest Ponzi scheme in history....
- Blog posts 2009-10-27
- Depomed Unfairly Slammed for Serada Phase III Results
- Under-the-radar drug delivery firm Depomed doesn't deserve the heat it's been taking on mixed results from two Phase III trials of hot flash drug Serada. by Trista Morrison
- Blog posts 2009-10-13
- Valassis v. NAM Federal Trial Set for February; Judge Denies Pretrial Motions
- Valassis and News America Marketing are set to enter a federal court trial in February over the former's claims that NAM illegally monopolized the supermarket advertising business, a source tells BNET. Separately, the two sides have entered mediation in their California state court case, suggesting that the...
- Blog posts 2009-09-08
- Immunomedics: P-Values? Phooey! These Lupus Data Look Great, Trust Us!
- Last week’s press release from Immunomedics and partner UCB concerning lupus drug epratuzumab’s success in a Phase IIb trial seemed to be missing something -- statistical significance. by Trista Morrison
- Blog posts 2009-08-31
- << Previous
- page 1 of 3
- Next >>
Content Types
Refining Tags
- Seeking Alpha (34 results)
- Call Transcript (32 results)
- Earnings (32 results)
- Finance (12 results)
- Patient (11 results)
- Jim Edwards (9 results)
- Business Operations (8 results)
- Marketing (5 results)
- Financial Accounting (5 results)
- Government (5 results)
- Healthcare (4 results)
- Federal Government (4 results)
- Investment (4 results)
- Targacept Inc. (3 results)
- Corporate Law (3 results)
- Litigation (3 results)
- Sales Strategy (3 results)
- Sales (3 results)
- Human Resources (3 results)
